Although the clinical-MRI features might overlap with multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and other central nervous system (CNS) demyelinating diseases, the International MOGAD Panel has recently published proposed criteria for the diagnosis of MOGAD [1]. The criteria proposed the presence of MOG-IgG as a core criterion, using MOG-IgG cell-based assays for diagnostic accuracy. The gene discussed is MOG; the disease is myeloid sarcoma.